CMC – Page 17 – Pharma.Tips

Design space poorly justified during regulatory submission – process robustness improvement framework

Improving Process Robustness: Addressing Poor Justification of Design Space in Regulatory Submissions In the evolving landscape of pharmaceutical manufacturing, one recurring challenge is the inadequate justification of the design space…

Control strategy inadequate during regulatory submission – process robustness improvement framework

Framework for Enhancing Process Robustness: Addressing Inadequate Control Strategies During Regulatory Submissions Inadequate control strategies during regulatory submissions can lead to significant process challenges and compliance risks for pharmaceutical manufacturers.…

CPPs not well defined during regulatory submission – data expectations for filings

Understanding the Impact of Poorly Defined CPPs on Regulatory Submissions In the pharmaceutical industry, the significance of well-defined Critical Process Parameters (CPPs) during regulatory submissions cannot be overstated. CPPs are…

Control strategy inadequate during development studies – data expectations for filings

Addressing Insufficient Control Strategies During Development Studies During the lifecycle of pharmaceutical products, an inadequately designed control strategy can lead to significant regulatory hurdles and product quality issues. This article…

Yield loss during optimization during pilot scale – regulatory scrutiny risk

Managing Yield Loss During Optimization in Pilot Scale: A Playbook for Regulatory Scrutiny Mitigation Yield loss during optimization in pilot scale processes can pose significant risks for pharmaceutical manufacturers aiming…

Process variability exceeds limits during validation planning – regulatory scrutiny risk

Managing Process Variability during Validation Planning for Regulatory Compliance In the pharmaceutical manufacturing landscape, exceeding process variability limits during validation planning presents a significant challenge that can raise regulatory scrutiny…

Design space poorly justified during validation planning – data expectations for filings

Addressing Inadequately Supported Design Space in Validation Planning: A Comprehensive Playbook In the complex world of pharmaceutical manufacturing, ensuring the robustness of your validation planning is crucial. One of the…

Design space poorly justified during development studies – process robustness improvement framework

Effective Framework for Addressing Poorly Justified Design Space in Development Studies In the pharmaceutical industry, poorly justified design spaces during development studies can pose significant risks to process robustness, regulatory…

Control strategy inadequate during validation planning – regulatory scrutiny risk

Mitigating Risks: Addressing Inadequate Control Strategies During Validation Planning In the fast-paced world of pharmaceutical manufacturing, an inadequate control strategy during validation planning can lead to increased regulatory scrutiny and…

Process variability exceeds limits during validation planning – preventing downstream validation failure

Managing Process Variability During Validation Planning to Prevent Subsequent Failures In pharmaceutical manufacturing, achieving consistent process performance is paramount for validation success. Process variability that exceeds accepted limits can signal…

QbD elements missing during tech transfer – preventing late-stage reformulation

Identifying QbD Elements Lacking During Tech Transfer to Avoid Late-Stage Reformulation The transfer of drug products from development to manufacturing is a critical phase that can significantly impact product quality…

Excipient incompatibility identified late during early development – how to redesign formulation strategy

Mitigating Late-Stage Excipient Incompatibility: A Comprehensive Formulation Redesign Playbook In the realm of pharmaceutical development, excipient incompatibility identified late in the process can derail timelines and inflate costs, leading to…